AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01780259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: 1 spray of 14 percent of esketamine solution (14 mg of esketamine per 100 microlitre) will be administered intranasally by nasal spray pump in each nostril once (Treatment A-total dose: 28 mg), twice with 5 minutes interval (Treatment B-total dose: 56 mg), thrice with 5 minutes interval between each repeated sprays (Treatment C-total dose: 84 mg), thrice with 10 minutes interval between each repeated sprays (Treatment D-total dose: 84 mg) and 4 times with 10 minutes interval between each repeated sprays (Treatment E-total dose: 112 mg). Treatment A, B, C, D will be administered in Cohort 1; Treatment D will be administered in Cohort 2; and Treatment E will be administered in Cohort 3.
Study NCT01780259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of oral placebo will be administered 5 minutes before the first intranasal spray of esketamine solution in the Treatment E of Cohort 3. Placebo solution (solution of water for injection with denatonium benzoate) will be administered intranasally solution by nasal spray pump in the Treatment F of Cohort 3.
Study NCT01780259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triazolam
Description: Single 0.25-mg oral dose of triazolam will be administered 5 minutes before the first intranasal spray of placebo solution in the Treatment F of Cohort 3.
Study NCT00613743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mouth wash with morphine
Description: morphine solution 0.2% concentration; 15ml per unit mouthwash 6 time à day
Study NCT00613743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo solution Quinine diHCl 0.3% at 50 mg/15 ml mouthwash 6 time/day
Study NCT03211117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT03211117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT03211117 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT03211117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03211117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03211117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT02348944 — intervention group
Intervention type: OTHER
Intervention: serum and urine sample
Description: Serum and urine samples will be collected at baseline, weeks2, 16, 52 and 68 to assess intra-individual biological variability of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 / FIB3-1 and FIB3-2.
Study NCT02137317 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LAPPE (locally adapted personal protective equipment)
Description: * Hand: Nitrile gloves flexible enough to grip pesticide container firmly and in a length appropriate for mixing and spraying such as wrist length. They should not contain lining inside. In case, nothing is available disposable plastic bags can provide sufficient protection. In both cases wearing a cotton glove underneath.~* Upper and lower body: As thick or as heavy cotton blouse and trousers as can be worn and plastic sheets cut as a long poncho.~* Feet: Unlined rubber boots or shoes at least calf height with thick cotton socks underneath with possibility for trousers to be worn outside rubber boots or shoes.
Study NCT02137317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAPPE (locally adapted personal protective equipment)
Description: * Hand: Nitrile gloves flexible enough to grip pesticide container firmly and in a length appropriate for mixing and spraying such as wrist length. They should not contain lining inside. In case, nothing is available disposable plastic bags can provide sufficient protection. In both cases wearing a cotton glove underneath.~* Upper and lower body: As thick or as heavy cotton blouse and trousers as can be worn and plastic sheets cut as a long poncho.~* Feet: Unlined rubber boots or shoes at least calf height with thick cotton socks underneath with possibility for trousers to be worn outside rubber boots or shoes.
Study NCT02481570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacokinetic simulation
Description: The aim of the simulation is to recommend dosing adjustments to improve postoperative analgesia with a rapid emergence.
Study NCT03328104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given once daily orally via mouth or NG tube beginning at Dose Level (DL) 1 (4 mg/m2/day). Depending on safety and tolerability, dose levels will be escalated to DL2 (5 mg/m2/day). There is also a dose level de-escalation to DL0 (3 mg/m2/day) if toxicity is noted at DL1. Begins at Day 1 through 28.
Study NCT03328104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Description: 650 mg/m2 IV daily x Day 1-5
Study NCT03328104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 440 mg/m2 IV x Day 1-5
Study NCT03328104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2 IV x Day 1-5
Study NCT03257527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENHANCE group
Description: The ENHANCE program includes an initial 3-month treatment of 12 weekly sessions (including an introductory session, a final session, and 10 content sessions) followed by a 3-month maintenance phase intervention with bi-weekly sessions. Over the course of the program, participants will learn about 10 evidenced-based principles of happiness and how these principles can be applied effectively in their lives. At the final session, participants will receive feedback outlining the happiness principles and activities that fit them best, and will then be asked to work on creating a plan for integrating those principles into their daily lives.
Study NCT03257527 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MBSR group
Description: The MBSR program is based on the self-help workbook entitled, A Mindfulness-Based Stress Reduction Workbook. This workbook is authored by Drs. Bob Stahl and Elisha Goldstein - who are both certified MBSR trainers. The workbook is written to help everyday people learn how to replace stress-promoting habits with mindfully-based ones to improve overall well-being. The workbook begins by providing a thorough introduction to the basic tenets of mindfulness, and improving well-being through the use of mindfulness-based skills. The workbook outlines, in detail, several skills-based exercises for practicing mindfulness across different aspects of a person's life. The MBSR group will be provided with a recommended weekly schedule for the initial 3-month treatment and a list of additional resources to be completed over the 3-month maintenance phase.
Study NCT00633880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
Study NCT00633880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: 100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
Study NCT02102607 — intervention group
Intervention type: OTHER
Intervention: age
Description: subjects stratified according to age: 20-30 years (Group 1), 31-40 years (Group 2), 41-50 years (Group 3), 51-60 years (Group 4), 61-70 years (Group 5), and 71-80 years (Group 6).
Study NCT02729883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02729883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete interviews
Study NCT02729883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive patient navigation via the Take the Fight strategists
Study NCT03667976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SATHI
Description: see above
Study NCT02336867 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Closure clip (OTSC® Proctology)
Study NCT02336867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closure clip (OTSC® Proctology)
Study NCT00583908 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens
Study NCT00301938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-hydroxystaurosporine
Description: Given IV
Study NCT00583908 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A toric
Description: toric contact lens
Study NCT00301938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine
Description: Given orally
Study NCT00301938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT05703906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation - VRRS Khymeia
Description: Participants will receive an individualized, multidomain exercise program set up by the therapist, based on their needs. The intervention applied will consist of 20 sessions of motor, language and/or cognitive training distributed in five sessions for week, each lasting 1 hour. Remotely, the therapist will supervise the participant's exercise program.
Study NCT00929942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SX-ELLA Stent Degradable DV Bronchial (DV Stent)
Description: Intervention SX-ELLA Stent Degradable DV Bronchial (DV Stent) will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented.
Study NCT03349502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG4101
Description: Administration of study drug (MG4101) for the patients with refractory or relapsed acute myeloid leukemia (Single arm)
Study NCT01868425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multimodal:acetaminophen, gabapentin, ketamine, bupivacaine
Description: acetaminophen, gabapentin, ketamine, bupivacaine and standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
Study NCT01868425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo pills and injectables
Description: receives standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane plus placebos of intervention arm meds
Study NCT03863015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab 20 Mg/mL Intravenous Solution
Description: Tocilizumab is suspended in isotonic saline to a total volume of 100mL prior to infusion
Study NCT03863015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Description: A one hour infusion of 100mL isotonic saline
Study NCT02271360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Dobesilate
Description: 1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
Study NCT00583908 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B toric
Description: toric contact lens
Study NCT02271360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Description: 1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
Study NCT03807960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: written form
Description: The written form which include PCA usage information.
Study NCT00583908 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens
Study NCT03807960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video
Description: The video about PCA usage
Study NCT03807960 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: routine care
Description: The routine description about PCA usage
Study NCT00749957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2-CB-hRPE65
Description: Recombinant adeno-associated virus vector expressing RPE65
Study NCT03582787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath MAC videolaryngoscopy
Description: Orotracheal intubation with McGrath MAC videolaryngoscopy after anesthetic induction
Study NCT03582787 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Macintosh Laryngoscopy
Description: Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
Study NCT04531098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac-Lot B
Description: Sci-B-Vac Lot B -10 μg of HBsAg, intramuscular injection of 10 μg/ml
Study NCT04531098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac-Lot A
Description: Sci-B-Vac Lot A - 10 μg of HBsAg, intramuscular injection of 10 μg/ml
Study NCT04531098 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Engerix-B (hepatitis B vaccine (recombinant)) is indicated for active immunization against hepatitis B virus infection
Study NCT02553642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Monotherapy Treatment - Nivolumab 240 mg flat dose Dosed q 2 weeks~OR~- Nivolumab 480 mg flat dose Dosed q 4 weeks~for up to 2 years from 1st dose of nivolumab or until loss of clinical benefit
Study NCT02553642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab
Description: Combination Treatment~* Ipilimumab 3 mg/kg~* Nivolumab 1 mg/kg Dosed q 3 weeks x 4 doses
Study NCT01018758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron will be given as an intravenous bolus at the dose of 250 micrograms over 30 seconds beginning 30 minutes before chemotherapy.
Study NCT03178370 — intervention group
Intervention type: DEVICE
Intervention: Gastric Electrical Stimulation
Description: Temporary and permanent gastric electrical stimulation
Study NCT01589367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin HCl 500mg(morning/evening) PO daily x 1week Metformin HCl 1000mg(morning)and 500mg(evening)PO daily x 1week Metformin HCl 1000mg(morning/evening) PO daily x 22weeks
Study NCT01589367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Letrozole 2.5mg PO daily + Placebo 1 tablet PO 2/day x 1week Letrozole 2.5mg PO daily + Placebo 2 tablet+ 1 tablet PO x 1 week Letrozole 2.5mg PO daily + Placebo 2 tablet PO 2/day x 22 weeks
Study NCT01059773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Patients weighting ≤ 100 kg will receive ustekinumab 45 mg at Weeks 0, 4 and 16. Patients who achieve a PASI 75 response at Week 28 and 40 will continue receiving ustekinumab 45 mg at Week 28 and 40. Patients who fail to achieve PASI 75 response at Week 28 will receive ustekinumab 90 mg at Week 28 and 40. Patients who achieve a PASI 75 response at Week 28, but fail to achieve PASI 75 response at Week 40 will receive ustekinumab 90 mg at Week 40. Patients > 100 kg will receive ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40, regardless of achievement of PASI 75 response. Consideration will be given to discontinuing treatment in these patients if they show no response at Week 28.
Study NCT01059773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Patients weighting ≤ 100 kg will receive ustekinumab 45 mg at Weeks 0, 4 and 16. Patients who achieve a PASI 75 response at Week 28 and 40 will continue receiving ustekinumab 45 mg at Week 28 and 40. Patients who fail to achieve PASI 75 response at Week 28 will receive ustekinumab 90 mg at Week 28 and 40. Patients who achieve a PASI 75 response at Week 28, but fail to achieve PASI 75 response at Week 40 will receive ustekinumab 90 mg at Week 40. Patients > 100 kg will receive ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40, regardless of achievement of PASI 75 response. Consideration will be given to discontinuing treatment in these patients if they show no response at Week 28.
Study NCT01714661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124
Description: Arms 1, 2
Study NCT01714661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm 3
Study NCT01059773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Gradual reduction of methotrexate therapy over the 4 week period after Week 0. The methotrexate dose reduction regime will depend on the dose of methotrexate at screening. All patients will stop methotrexate regardless of the final dose after 4 overlapping weeks. The last dose of methotrexate will be given within the 7 day period before the second dose of ustekinumab.
Study NCT01934348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological First Aid
Study NCT01934348 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual victim advocacy Services
Study NCT06307717 — intervention group
Intervention type: DRUG
Intervention: volatile anaesthetic (sevoflurane, isoflurane, desflurane)
Description: Patients receiving volatile anaesthetics received at least one volatile anaesthetic (sevoflurane, isoflurane, desflurane), and those who received non-volatile anaesthetics did not receive any volatile anaesthetic.
Study NCT03339232 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: BCAA Supplement
Description: Each teaspoon contains 1788 mg of BCAA and participants will take 7 teaspoons (12.5 grams of BCAA) per day divided into three separate servings. Each teaspoon contains L-leucine, isoleucine and valine in a 2:1:1 ratio.
Study NCT03339232 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical Activity
Description: Supervised low impact aerobic physical activity for one hour each week.
Study NCT00413205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily
Study NCT00413205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAR Gamma
Description: 5mg po daily
Study NCT00644163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eban HIV/STD Risk Reduction Intervention
Description: The eight-session Eban HIV/STD Risk Reduction Intervention is embedded in a cultural context and is gender tailored in its prevention messages and activities. Sessions will focus on the couple and will teach the couple about communication skills. The approach will draw upon social cognitive theory, an ecological framework, and HIV/STD risk-reduction research with inner-city African-American populations.
Study NCT00644163 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eban Health Promotion Intervention
Description: The eight-session Eban Health Promotion Intervention is guided by a social cognitive approach that engages health promotion skills. Sessions will focus on the individual and will provide factual information on health, screening, exercise, diet management, and medication adherence.
Study NCT02248064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-titrating oxygen system
Description: The auto-titrating oxygen system contains a number of components working together to produce variable oxygen flow. An oximeter measures the oxygen saturation of a patient and via Bluetooth this is relayed to a control centre in a mobile phone. This in turn regulates a flow meter which adjust oxygen flow.
Study NCT01526785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa
Description: 4000 L alglucosidase alfa administered by IV infusion at the same dose and dose regimen used for the patient's routine treatment prior to the study for 52 weeks.
Study NCT00746226 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus acidophilus and Bifidobacterium lactis
Description: Daily 5x10\^9 CFU of a combination of L. acidophilus and B. lactis
Study NCT00746226 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose~As capsule which could be opened
Study NCT02842476 — intervention group
Intervention type: DEVICE
Intervention: Disposable Sensor
Description: Two adhesive based Pulse Oximeter Probes, S0136J-L were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.
Study NCT02842476 — intervention group
Intervention type: DEVICE
Intervention: Reusable Sensor
Description: Two soft reusable Pulse Oximeter Probes, Model S0080D-S were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.
Study NCT02842476 — intervention group
Intervention type: DEVICE
Intervention: Control Pulse Oximetry
Description: A Clinimark Control Pulse Oximetry system was also placed on the subject to evaluate the stability of the draws.
Study NCT05952921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthwash
Description: Concentration rinse with 0.05% HOCl
Study NCT05952921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: A high concentration of 0.2% CHX (7 days), followed by 0.012% CHX (14 days).
Study NCT02871141 — intervention group
Intervention type: PROCEDURE
Intervention: electroconvulsive therapy
Description: electroconvulsive therapy
Study NCT02871141 — intervention group
Intervention type: DRUG
Intervention: Antidepressant
Description: Antidepressant